The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Srinivasan, M.
Right arrow Articles by Kaumaya, P. T. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Srinivasan, M.
Right arrow Articles by Kaumaya, P. T. P.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
The Journal of Immunology, 2001, 167: 578-585.
Copyright © 2001 by The American Association of Immunologists

A Retro-Inverso Peptide Mimic of CD28 Encompassing the MYPPPY Motif Adopts a Polyproline Type II Helix and Inhibits Encephalitogenic T Cells In Vitro1

Mythily Srinivasan*, Richard M. Wardrop{dagger}, Ingrid E. Gienapp{dagger}, Scott S. Stuckman{dagger}, Caroline C. Whitacre{dagger},§ and Pravin T. P. Kaumaya2,*,{ddagger},§

Departments of * Microbiology, College of Biological Sciences; {dagger} Molecular Virology, Immunology, and Medical Genetics; {ddagger} Obstetrics and Gynecology, College of Medicine and Public Health; and § Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210 response unit(s); MBP, myelin basic protein; CD, circular dichroism/dichroic; {theta} = mean residue molar ellipticity; SPR, surface plasmon resonance; L-CD28, CD28 free peptide; EL-CD28, end group-blocked CD28; RI-CD28, end group-blocked retro-inverso CD28; RL-CD28, end group-blocked reverse L CD28; D-CD28, end group-blocked D-CD28; LNC, lymph node cell(s).

Complete activation of T cells requires two signals: an Ag-specific signal delivered via the TCR by the peptide-MHC complex and a second costimulatory signal largely provided by B7:CD28/CTLA-4 interactions. Previous studies have shown that B7 blockade can either ameliorate experimental autoimmune encephalomyelitis by interfering with CD28 signaling or exacerbate the disease by concomitant blockade of CTLA-4 interaction. Therefore, we developed a functional CD28 mimic to selectively block B7:CD28 interactions. The design, synthesis, and structural and functional properties of the CD28 free peptide, the end group-blocked CD28 peptide, and its retro-inverso isomer are shown. The synthetic T cell-costimulatory receptor peptides fold into a polyproline type II helical structure commonly seen in regions of globular proteins involved in transient protein-protein interactions. The binding determinants of CD28 can be transferred onto a short peptide mimic of its ligand-binding region. The CD28 peptide mimics effectively block the expansion of encephalitogenic T cells in vitro suggesting the potential usefulness of the peptides for the treatment of autoimmune disease conditions requiring down-regulation of T cell responses.




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
M. Srinivasan, D. Lu, R. Eri, D. D. Brand, A. Haque, and J. S. Blum
CD80 Binding Polyproline Helical Peptide Inhibits T Cell Activation
J. Biol. Chem., March 18, 2005; 280(11): 10149 - 10155.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Srinivasan, I. E. Gienapp, S. S. Stuckman, C. J. Rogers, S. D. Jewell, P. T. P. Kaumaya, and C. C. Whitacre
Suppression of Experimental Autoimmune Encephalomyelitis Using Peptide Mimics of CD28
J. Immunol., August 15, 2002; 169(4): 2180 - 2188.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2001 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2001 by The American Association of Immunologists, Inc. All rights reserved.